α7 Nicotinic acetylcholine receptor-mediated anti-inflammatory effect in a chronic migraine rat model via the attenuation of glial cell activation

Qing Liu, Chaoyang Liu, Li Jiang, Maolin Li, Ting Long, Wei He, Guangcheng Qin, Lixue Chen, Jiying Zhou

Department of Neurology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China; Laboratory Research Center, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China

Background: Evidence suggests that the activation of α7 nicotinic acetylcholine receptor (α7nAChR) can greatly decrease the neuroinflammation response. Neuroinflammation plays a pivotal role in the pathogenesis of chronic migraine (CM). Clinical observations also show that nicotine gum induces analgesic effects in migraine patients. However, whether α7nAChR is involved in CM is unclear.

Objective: To investigate the role of α7nAChR in CM and provide a new therapeutic target for CM.

Materials and methods: Thirty-six male Sprague–Dawley rats were distributed randomly into control, CM, PNU-282987, and α-bungarotoxin groups (n=9 rats in each group). The CM model was established by the recurrent daily administration of inflammatory soup on the dura over the course of 1 week. The hind paw threshold and facial allodynia were assessed by the von Frey test. The expression levels of α7nAChR, tumor necrosis factor-alpha, and interleukin-1 beta were analyzed by Western blot and real-time fluorescence quantitative polymerase chain reaction. The location of α7nAChR in the hippocampus was quantified by immunofluorescence, as well as the microglial and astrocyte alterations. Changes in the calcitonin gene-related peptide and the phosphorylated JNK protein among different groups were measured by Western blot.

Results: We found that the expression of α7nAChR was reduced after repeated inflammatory soup administration. The increased expression of tumor necrosis factor-alpha, interleukin-1 beta, and calcitonin gene-related peptide in CM group were significantly decreased by PNU-282987 and aggravated by α-bungarotoxin. Moreover, PNU-282987 decreased the numbers of astrocytes and microglia compared with the numbers in the CM group in both hippocampal CA1 and CA3 regions. In contrast, α-bungarotoxin activated the astrocytes and microglia, but the differences with respect to the CM group were not significant. Activated c-Jun N-terminal kinase signaling was observed in CM rats and was also blocked by PNU-282987.

Conclusion: The activation of α7nAChR increased the mechanical threshold and alleviated pain in the CM rat model. α7nAChR activation also decreased the upregulation of astrocytes and microglia through the p-c-Jun N-terminal kinase–mitogen-activated protein kinase signaling pathway.

Keywords: chronic migraine, α7nAChR, analgesia, glial activation, neuroinflammation, nociception

Introduction
Patients with chronic migraine (CM) exhibit functional disability, and CM is refractory to treatment. However, the pathophysiological mechanisms of CM are complex and have not yet been fully established. Numerous studies suggest that pro-inflammatory...
cytokine levels are increased in CM, and recent evidence has also indicated that the transcription of inflammatory genes is upregulated in CM patients. This finding implies that inflammation, especially neuroinflammation, is part of the core pathogenesis of CM. In vivo and in vitro experiments have demonstrated that the activation of astrocyte and microglia accelerates the expression of pro-inflammatory cytokines and have also shown that microglial activation contributes to acute pain and that astrocyte activation, in turn, maintains allodynia. Furthermore, both microglia and astrocytes were recently showed to participate in cortical spreading depression-related diseases, such as migraine. Therefore, we assumed the cause of the inflammatory cytokine expression in CM to be the activation of glial cells.

Clinical research has shown that nicotine gum has an analgesic effect. Cholinergic modulation attenuates systemic inflammatory responses. A prophylactic approach to migraine involves the activation of the cholinergic anti-inflammatory pathway (CAP). α7 nicotinic acetylcholine receptor (α7nAChR) is one of the ligand-gated ion channels in the CAP. After combining with signaling molecules, these ionic channel-linked receptors could significantly modulate the membrane permeability and neurotransmitter expression. A series of studies have proved that α7nAChRs participate in neuroprotection. α7nAChR activation exhibits significant anti-inflammatory effects in neuroinflammation, and α7nAChR agonists have also been shown to attenuate hyperalgesic effects in chronic neuropathic pain. In a previous rodent study, deficient antinociceptive effects were observed in α7nAChR knockout mice compared with their littermate controls when treated with choline. The activation of astrocytes and microglia is known to play a pivotal role in the progression of pain. Furthermore, numerous studies have demonstrated that α7nAChR activation significantly suppresses glial activation. An in vitro trial showed that the activation of α7nAChR promoted the conversion of M1 microglia to the M2 phenotype. These results suggest that activated α7nAChR may contribute to the inhibition of glial activation and further to the regulation of CM conditions. However, to date, this assumption has not been verified in a CM rat model.

Hippocampus had long been associated with cognitive, while more and more studies showed that the hippocampus was involved in pain-related attention and pain processing, such as migraine. Clinical studies suggested the hippocampal volume was initially changed in low frequency migraines, this plasticity maladaptive decreased in the long term in CM. The hippocampal activation was also linked to headache frequency. α7nAChRs were predominant in hippocampal CA1, CA3 layers and dentate gyrus layer, both in humans and rodents. PNU-282987 was an agonist of α7nAChR and its effect could be completely blocked by α-bungarotoxin. Calcitonin gene-related peptide (CGRP) is a potent vasodilator and pain-signaling neuropeptide and is strongly implicated in the pathophysiology of migraine. CGRP is a trigger of migraine attacks. CGRP antibodies had shown promising effects in both episodic migraine and CM. Pro-inflammatory cytokine, especially tumor necrosis factor-alpha (TNF-α), might increase the production of CGRP and exacerbate the pathophysiology of migraine. Cytokines were known to activate different signaling pathways, such as the mitogen-activated protein kinase (MAPK) pathways. MAPK cascade also increased CGRP expression during migraine. A vivo experiment suggested that the c-Jun N-terminal kinase (JNK) signaling pathway was obligate to the manifestation of inflammatory soup (IS)-induced nociceptive behavior. Consequently, we speculated that α7nAChR might work through the phosphorylated (p)-JNK–MAPK signaling pathway.

We aimed to explore whether α7nAChR activation produces anti-allodynic and anti-inflammatory effects in a rat model of CM. PNU-282987 and α-Bungarotoxin were used to further explore its role in the neuroimmune activity of the central nervous system (CNS).

Materials and methods

Animals

Healthy adult male Sprague–Dawley rats weighing 260–320 g were housed 1 per cage at a temperature of 23°C ± 1°C and a 12-hour light-dark cycle with food and water available ad libitum. All treatment protocols were performed according to the guidelines of the Animal Care and Use Committee at Chongqing Medical University in China and were consistent with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The Animal Care and Use Committee at Chongqing Medical University approved this research. Since the animals were to be in pain, the number of rats studied was restricted to the minimum necessary. The final numbers are detailed in each figure.

CM model

Based on previous research, 8.0 g (facial) and 15.0 g (hind paw) were used as tactile stimulus thresholds. Repeated meningeal administration of IS was used to study nociception in CM. All animals were placed in a stereotaxic apparatus.
(ST-51603; Stoelting Co., Chicago, IL, USA) after general anesthesia. The rats were sterilized with chlorhexidine (10% solution) and then fitted with a cranial chamber. A craniotomy 1 mm in diameter (+1.5 mm from the bregma and +1 mm lateral) was performed above the dura, with care not to damage the dura. A stainless steel cannula with a removable cap (catalog no. 62101/62001; RWD, Shenzhen, China) was affixed to the bone with dental cement. After suturing, the rats were returned to a temperature-controlled electric heating blanket until recovery was complete and they regained consciousness. After 1 week of recovery, the meningeal administration of IS or PBS was successively performed for 7 days.

Groups and treatment
Rats were randomly divided into 4 groups: the control, CM, PNU-282987, and α-bungarotoxin groups. In the control group, 2 μL of PBS (0.1 M, pH 7.4) was slowly infused through the cannula. In the other 3 groups, 2 μL of IS was infused. The IS contained 1 mM histamine, serotonin, and bradykinin and 0.1 mM prostaglandin E2 (all from Sigma, St. Louis, MO, USA). After 7 days of exposure by infusion, the vehicle (PBS, 0.1 M, pH 7.4) was administered by intracerebroventricular (I.C.V) injection to the control and CM groups, and PNU-282987 (2.5 μmol/animal, P6499-10MG; Sigma) and α-bungarotoxin (1.0 μg/animal, ab120542; Abcam, Cambridge, MA, USA) were administered to the PNU-282987 and α-bungarotoxin groups, respectively (on the eighth day; Figure 1). The optimal doses were based on previous studies in rats.49,50

Mechanical allodynia (von Frey test)
Clinical studies have shown that most CM patients complain of allodynia after repeated migraine attacks.51,52 To explore the occurrence of allodynia in CM, we used the von Frey test to detect the mechanical threshold. Before testing, the rats were habituated to the testing apparatus (30×15×17 cm) for 15 min. The von Frey test was performed on the hind paws ipsilateral to the surgery and at the midline of the forehead where the ophthalmic nerve distributed as described previously.53,54 A positive response for the von Frey test was recorded when the rat retracted its head or hind paw from the rigid tip. Mechanical allodynia was evaluated before IS or PBS infusion and 24 h after I.C.V injection of the vehicle, PNU-282987 or α-bungarotoxin.

Quantitative real-time polymerase chain reaction (PCR)
The total RNA from the hippocampus tissue was isolated by using TRIzol reagent (Takara, Dalian, China). cDNA was amplified using the PrimeScript™ RT Reagent Kit (Takara) in 96-well PCR plates (Bio-Rad, Hercules, CA, USA). The PCR conditions were initiated with 1 cycle at 95°C for 30 s, followed by 50 cycles of 95°C for 5 s and 50°C (for TNF-α and interleukin-1 beta [IL-1β]) or 60°C (for α7nAChR) for 30 s. The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control.

The primer sequences were synthesized by Sangon Bio-tech Company (Shanghai, China). The primer sequences used in this study were as follows: 1) α7nAChR (GenBank: NM_012832): F: 5′-GCAAAGAGGCCATACCCAG-3′; R: 5′-CAGCAAGAATACCCAGCAG-3′; 2) TNF-α (GenBank: D00475): F: 5′-CTTCAAGGGAAGGCTG-3′; R: 5′-GAGCCTGTACCTTCTG-3′; 3) IL-1β (GenBank: M98820): F: 5′-TACCTATGCTTTGCGTCAG-3′; R: 5′-ATCATTCCAGGATCAGAG-3′; 4) GAPDH (GenBank: M17701): F: 5′-TCTGGCAACACAGACGCT-3′; R: 5′-AGTGGCATGTAGGGACT-3′.

Western blot (WB) analysis
The proteins of the hippocampus were homogenized in radioimmunoprecipitation assay lysis buffer (sc-24948; Santa Cruz, Dallas, TX, USA) with phosphatase inhibitor (Boster, Wuhan, China) and protease inhibitor (Beyotime, Shanghai, China). We examined the expression of α7nAChR, TNF-α, IL-1β, CGRP, and p-JNK using Western blotting as previously described.55 The primary antibodies were α7nAChR (1:200, sc-58607), TNF-α (1:500, sc-52B83), IL-1β (1:500, sc-12742), CGRP (1:500, sc-57053), p-JNK (1:500, sc-6254), and β-actin (1:4000, 20536-1-AP). The immunoreacted bands were visualized with a BeyoECL Plus Kit (P1008; Beyotime) and quantified with an imaging system (Fusion, Munich, Germany).
Immunofluorescence staining
After anesthesia, the rats were perfused transcardially with chilled saline followed by 4% paraformaldehyde (PFA). The inner (medial) region of the temporal lobe (where the hippocampus is located) was subsequently removed and post-fixed overnight in 4% PFA at 4°C, then dehydrated with 20% sucrose for 24 h followed by 30% sucrose for 48 h. Sections 20 μm thick were cut with a cryostat (Leica, Wetzlar, Germany). The hippocampus sections were permeabilized with 0.3% Triton X-100 (Beyotime) at room temperature for 10 min. Incubation was performed overnight at 4°C with the following primary antibodies: α7nAChR (1:200, sc-58607), polyclonal goat anti-rat glial fibrillary acidic protein (GFAP, 1:100, ab49874), and ionized calcium binding adaptor molecule 1 (Iba1, 1:100, ab5076). After washing with PBS, the α7nAChR sections were additionally incubated with goat anti-rat Cy3-conjugated secondary antibodies (1:6000, bs-0293G-HRP), while Iba1 sections were incubated with donkey anti-goat Cy3-conjugated secondary antibodies (A0502; Beyotime). Then, all sections were incubated with 4,6-diamino-2-phenyl indole (DAPI) staining solution (C1005; Beyotime) and analyzed with a confocal laser scanning fluorescence microscope (Olympus, Tokyo, Japan).

Immunofluorescence staining was conducted in 3 animals per treatment group, with 3 representative hippocampus sections per animal. The number of positive cells was calculated as the mean of the aforementioned numbers.

Statistical analysis
The data are presented as the mean ± SEM. Parametric data were analyzed by one-way analysis of variance and the Tukey post hoc method. The differences between 2 groups were compared using the unpaired t-test. SPSS 20.0 was used for statistical analysis. A value of p<0.05 was considered to represent statistically significant, while p<0.01 represented much more statistically significant.

Results
Decrease in hind paw withdrawal and periorbital threshold after recurrent IS injection and the effects of α7nAChR
Before the trials, no significant difference was observed in the mechanical threshold between the control and CM groups (Figure 2A). The paw withdrawal and periorbital threshold both decreased after the first infusion of IS with respect to the control (p<0.05). After the second infusion, the differences became more significant (p<0.01). These effects persisted until the final administration 1 week later.

To investigate the role of α7nAChR on alldynia in CM rats, we used PNU-282987 (α7 agonist) or α-bungarotoxin.

Figure 2 The decreased mechanical threshold in the CM group (relative to the control) was mitigated by PNU-282987 but aggravated by α-bungarotoxin.
Notes: (A) The mechanical threshold of alldynia decreased in the CM group in hind paw stimulation (*p<0.05, **p<0.01 versus control group). (B) The hind paw withdrawal and periorbital threshold were somewhat decreased after the intracerebroventricular injection of α-bungarotoxin. The periorbital threshold was increased by PNU-282987. An increasing trend, but no significant difference, was observed between the CM and PNU-282987 groups (*p>0.05 versus CM group) (n=9 per group).
Abbreviations: α-B, α-bungarotoxin; CM, chronic migraine; Con, control; PNU, PNU-282987.
α7nAChR activation diminished nociception in CM rats

Before I.C.V injection, no significant difference was observed in the CM, PNU-282987, and α-bungarotoxin groups (Figure 2B, p>0.05). I.C.V injection of PNU-282987 exerted a protective effect against allodynia; the periorbital threshold improved significantly after 24 h (p<0.05), while the hind paw withdrawal threshold showed an ascending trend (p>0.05). The administration of α-bungarotoxin led to aggravation of both the hind paw withdrawal and periorbital threshold (Figure 2B, p<0.05).

Recurrent IS injection decreased α7nAChR expression in the hippocampus

The expression of α7nAChR in the control and CM groups was measured by PCR and Western blotting (Figure 3). Analysis showed that the protein level of α7nAChR decreased significantly after the repeated administration of IS (**p<0.01, Figure 3A). To investigate the cause, we performed mRNA-level verification and found that the mRNA level of α7nAChR was also significantly reduced (***p<0.01, Figure 3B). These data indicated that recurrent IS injection significantly decreased α7nAChR expression in the hippocampus.

Expression of α7nAChR in hippocampal CA1, CA3, and dentate gyrus regions

The distribution of α7nAChR was most in hippocampus, especially CA1, CA3, and dentate gyrus layers. So we chose these regions to study α7nAChR in CM. PNU-282987 (agonist of α7) and α-bungarotoxin (antagonist of α7) were performed respectively and immunofluorescence staining analyses were used to explore the α7nAChR expression in the 3 hippocampal areas of the 4 groups (Figure 4). The α7nAChR was significantly decreased in hippocampal CA1, CA3, and DG regions in the CM group than the control. The expression of α7nAChR in hippocampal CA1 and CA3 regions was increased after administration of PNU-282987 (**p<0.01, Figure 4C); however, there were no changes in DG region. There was no statistical significance between the CM and α-bungarotoxin groups in all the 3 regions. It indicated that activated α7nAChR in hippocampal CA1 and CA3 might be mainly responsible for reducing inflammation in central neuroimmune.

Effects of α7nAChR on the activation of astrocytes and microglia in the hippocampal CA1 and CA3 areas in CM rats

The astrocytes and microglia were significantly activated in the CM group in both hippocampal CA1 and CA3 regions, showing swollen cell bodies and synaptic coarsening (Figure 5). In contrast, their morphology in the control group showed smaller cell bodies. In CA1 area, the number of Iba-1-positive cells decreased after the administration of PNU-282987 (63.94±6.31 versus CM group, Figure 5A) and showed a decreasing trend with respect to the control group (p>0.05). The numbers of GFAP-labeled cells (68.50±2.75) and Iba-1-positive cells (100.50±4.94) in the CM group were significantly higher than those in the control group (24.50±4.15 and 80.41±3.13, respectively). After the administration of PNU-282987, the number of GFAP-labeled cells (26.00±2.05) was lower than that in the CM group but was still higher than that in the control group, indicating that the activation of astrocytes was partially inhibited. The α-bungarotoxin group also showed
activation of astrocytes and microglia in the hippocampus CA1 area, but the difference with respect to the CM group was not statistically significant. In CA3 area, the numbers of GFAP-positive cells were also partially inhibited by PNU-282987, but Iba-1-positive cells were shown to be the statistically significant compared with the control group ($p<0.01$, Figure 5B).

Effects of PNU-282987 or $\alpha$-bungarotoxin on the expression of TNF-$\alpha$, IL-1$\beta$, and CGRP in the hippocampus

As shown in Figure 6A, TNF-$\alpha$ and IL-1$\beta$ were significantly elevated in the CM group ($p<0.01$), while PNU-282987
α7nAChR activation diminished nociception in CM rats

significantly decreased the elevated levels \( (p<0.01) \). In contrast, α-bungarotoxin aggravated the expression of IL-1β \( (p<0.01) \) and showed a tendency to increase TNF-α \( (p>0.05) \). We also observed the increased mRNA expression levels of TNF-α and IL-1β \( (p<0.01) \). The administration of PNU-282987 showed an inhibitory effect on TNF-α \( (p<0.05) \) and IL-1β \( (p<0.01) \). α-bungarotoxin increased the mRNA expression of TNF-α \( (p<0.05) \) and IL-1β \( (p<0.01) \). These results demonstrated that the IS-induced increase in pro-inflammatory cytokines could be regulated by α7nAChR.

We observed a substantial increase in CGRP protein in the hippocampus in CM rats \( (p<0.01) \, \text{Figure 6C} \). This increase was abolished by the administration of PNU-282987 \( (p<0.01) \) and aggravated by the administration of α-bungarotoxin \( (p<0.01) \).

Effects of α7nAChR agonist and antagonist administration on p-JNK–MAPK expression in CM rats

To verify whether phosphorylated JNK participates in CM pathophysiology and whether its regulation is related to α7nAChR, we examined the expression of the p-JNK protein using WB analysis. The results revealed that the level of p-JNK was increased in the CM group and suppressed by PNU-282987 \( (p<0.01) \, \text{Figure 7} \). No significant differences were observed between the CM and α-bungarotoxin groups.

Discussion

In this study, we verified that α7nAChR in the hippocampal microglia and astrocytes plays a role in CM pathophysiology.
Our current data indicate the following: 1) α7nAChR expression was decreased in CM rats; 2) repeated epidural injections of IS accelerated TNF-α and IL-1β expression and promoted the neurogenic inflammation that is the core reason for CM; 3) α7nAChR activation decreased the expression of pro-inflammatory cytokines and induced analgesic effects in CM; and 4) the activation of microglia and astrocytes in CM was suppressed by the I.C.V injection of PNU-282987.

Previous studies have suggested that α7nAChRs are expressed predominantly in hippocampal GABAergic interneurons, as well as microglial cells and astrocytes. Their impaired function was attributed partly to the decreased expression of α7nAChRs. Mice with α7nAChR mutation (knockout [KO]) displayed significantly lower paw withdrawal latency in chronic inflammatory and neuropathic pain, while its complementary α7 hypersensitive mice (knock in [KI]) exhibited the opposite effect. Intraperitoneal administration of α7nAChR-positive allosteric modulator could also reduce allodynia in an inflammatory pain model. These results suggested that the decrease in α7nAChR was a cause of allodynia in neuropathic pain. Our study extended these findings by demonstrating the downregulated expression of α7nAChR in CM. To the best of our knowledge, this study is the first to examine α7nAChR expression in a rat CM model.

Figure 6 WB and PCR data showed dynamic changes in TNF-α, IL-1β, and CGRP.

Notes: (A) The IS-induced increases in TNF-α and IL-1β were both significantly inhibited by PNU-282987 (**p<0.01 versus control, *p<0.01 versus CM). In the α-bungarotoxin-treated group, TNF-α showed a tendency to increase compared with the value in the CM group (p>0.05), while IL-1β showed a significant increase (p<0.01). (B) mRNA data for TNF-α and IL-1β (*p<0.05 and **p<0.01 versus control, *p<0.05 and **p<0.01 versus CM). (C) The IS-induced increase in CGRP protein expression was significantly inhibited after PNU-282987 administration. In contrast, α-bungarotoxin stimulated a further increase in CGRP expression (**p<0.01 versus control, *p<0.01 versus CM). All data are expressed as the mean ± SEM, n=6 per group.

Abbreviations: α-B, α-bungarotoxin; CGRP, calcitonin gene-related peptide; CM, chronic migraine; Con, control; IS, inflammatory soup; PCR, polymerase chain reaction; PNU, PNU-282987; WB, Western blot.
Clinical trials showed increased gene expression levels and serum levels of pro-inflammatory cytokines in the migraine attack group, which indicated the pivotal role of neuroinflammation in migraine pathogenesis. The recurrent epidural administration of IS resulted in allodynia-like effects and pro-inflammatory cytokine expression, which had been considered features of CM. The results of our study agreed with the literature in this respect. In this study, a parallel increase in TNF-α with the literature in this respect. In this study, a parallel increase in TNF-α and IL-1β was observed after the recurrent epidural administration of IS. TNF-α and IL-1β were also both significantly suppressed after the I.C.V injection of PNU-282987. In the behavioral experiment, the allodynia induced by CM was alleviated after the PNU-282987 intervention. Therefore, we speculated that α7nAChR expression might correlate with CM allodynia. Our study also demonstrated that the elevation of pro-inflammatory cytokines enhanced the CGRP-induced central sensitization. An inflammatory pain model showed that the activated α7nAChR induced antiallodynic responses through modulate micro glial activation in hippocampus. Furthermore, previous results also suggested that microglial activation preceded astrocytic activation and that astrocytes maintained the hypersensitivity. Our study provided additional supporting evidence that microglia and astrocytes in the CNS mediated the progression of CM. The upregulation of microglia and astrocytes in CM rats was reversed by PNU-282987. Pro-inflammatory cytokines were also suppressed, inducing analgesic effects in CM.

Previous studies implicated the JNK–MAPK pathway in the development of glial activation. As one of the most important members of the MAPK family, JNK was also found to be activated in neuropathic pain. Our data illustrated that the alleviation of activated glia and pain behavior was ameliorated by the activation of α7nAChR. Therefore, we hypothesized that the effect might proceed through this complex downstream signaling pathway. The increased expression of phosphorylated JNK in CM rats was significantly inhibited by the I.C.V injection of PNU-282987, which was consistent with previous reports. Furthermore, downregulation of TNF-α and IL-1β was observed (Figure 8). There was no significant difference in p-JNK expression between the α-bungarotoxin and CM groups, it might be because of the limited timeframe or the small doses.

This study is entirely novel in that it investigates the previously unmeasured α7nAChR level in a rat model of CM. The levels of activated astrocytes and microglia and inflammatory cytokine expression have also been compared to illuminate the mechanism of CM pathophysiology. Future studies using chronic administration regimens would also be of interest to determine whether the long-term activation of α7nAChR results in differential effects in CM.

**Conclusion**

The activation of α7nAChR inhibits the activation of astrocytes and microglia in CM through the p-JNK–MAPK signaling pathway. Increased levels of TNF-α, IL-1β, and CGRP in the nociceptive network are related to the pathophysiological dysfunctions in CM and α7nAChR activation could inhibit
their expression. With this work, we aim to contribute to the development of a potential therapeutic target in CM.

Acknowledgments
The authors would like to thank Tiwei Fu for his work on the confocal laser scanning fluorescence tests. Special thanks are due to the Laboratory Research Center of the First Affiliated Hospital of Chongqing Medical University for the animal husbandry support. This study was supported by the National Natural Science Foundation of China (no. 81671092) and the Natural Science Foundation Project of Chongqing Science and Technology Commission (no. cstc2013jjB10009).

Disclosure
The authors report no conflicts of interest in this work.

References
1. Bigal ME, Rapoport AM, Lipton RB, Toper SJ, Sheftell FD. Assessment of Migraine Disability Using the Migraine Disability Assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache. 2003;43(4):336–342.
2. Rozen T, Svidan SZ. Elevation of CSF tumor necrosis factor alpha levels in new daily persistent headache and treatment refractory chronic migraine. Headache. 2007;47(7):1050–1055.
3. Pusic KM, Pusic AD, Kemme J, Kraig RP. Spreading depression requires α7 nicotinic acetylcholine receptor agonist attenuates gp120-induced mechanical allodynia and spinal pro-inflammatory cytokine profiles in rats. Brain Behav Immun. 2010;24(6):959–967.
4. Aurora SK. Spectrum of illness: understanding biological patterns and relationships in chronic migraine. Neurology. 2009;72(Suppl 8):S1–S13.
5. Zhao J, Brooks DM, Lorrie DI. Lipopolysaccharide-activated SHP-1-deficient motheaten microglia release increased nitric oxide, TNF-alpha, and IL-1beta. Glia. 2006;53(3):304–312.
6. Green AJ, Lipton RB, Lipton MR. Nicotine gum withdrawal and migraine headaches. Cephalalgia. 2009;29(3):256–265.
7. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature. 2003;421(6921):384–388.
8. Stevens TR, Krueger SR, Fitzsimonds RM, Picciotto MR. Neuroprotection by nicotine in mouse primary cortical cultures involves activation of calcineurin and L-type calcium channel inactivation. J Neurosci. 2003;23(31):10093–10099.
9. Frasch MG, Sznynkaruk M, Prout AP, et al. Decreased neuroinflammation correlates to higher vagus nerve activity fluctuations in near-term ovine fetuses: a case for the afferent cholinergic anti-inflammatory pathway? J Neuroinflammation. 2016;13(1):103.
53. Rubboli F, Court JA, Sala C, et al. Distribution of nicotinic receptors in the human hippocampus and thalamus. *Eur J Neurosci*. 1994;6(10):1596–1604.

54. Baddick CG, Marks MJ. An autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutants. *Biochem Pharmacol*. 2011;82(8):828–841.

55. Fabian-Fine R, Skelel P, Errington ML, et al. Ultrastructural distribution of the α7 nicotinic acetylcholine receptor subunit in rat hippocampus. *J Neurosci*. 2001;21(20):7993–8003.

56. Garcia-Rates S, Camarasa J, Sanchez-Garcia AI, Gandia L, Escudero E, Pubill D. The effects of 3,4-methylenedioxymethamphetamine (MDMA) on nicotinic receptors: intracellular calcium increase, calpain/caspase 3 activation, and functional upregulation. *Toxicol Appl Pharmacol*. 2010;244(3):344–353.

57. Schedel A, Thornton S, Schloss P, Klüter H, Bugert P. Human platelets express functional α7-nicotinic acetylcholine receptors. *Arterioscler Thromb Vasc Biol*. 2011;31(4):928–934.

58. Hershey AD. CGRP – The next frontier for migraine. *N Engl J Med*. 2017;377(22):2190–2191.

59. Giambardino MA, Costantini R. Challenging chronic migraine: targeting the CGRP receptor. *Lancet Neurol*. 2017;16(6):410–411.

60. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for episodic dural stimulation in awake rats. *Headache*. 2015;55(11):1961–1969.

61. Fabian-Fine R, Skehel P, Errington ML, et al. Ultrastructural distribution of the α7 nicotinic acetylcholine receptor subunit in rat hippocampus. *J Neurosci*. 2001;21(20):7993–8003.

62. Garcia-Rates S, Camarasa J, Sanchez-Garcia AI, Gandia L, Escudero E, Pubill D. The effects of 3,4-methylenedioxymethamphetamine (MDMA) on nicotinic receptors: intracellular calcium increase, calpain/caspase 3 activation, and functional upregulation. *Toxicol Appl Pharmacol*. 2010;244(3):344–353.

63. Schedel A, Thornton S, Schloss P, Klüter H, Bugert P. Human platelets express functional α7-nicotinic acetylcholine receptors. *Arterioscler Thromb Vasc Biol*. 2011;31(4):928–934.

64. Rubboli F, Court JA, Sala C, et al. Distribution of nicotinic receptors in the human hippocampus and thalamus. *Eur J Neurosci*. 1994;6(10):1596–1604.

65. Baddick CG, Marks MJ. An autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutants. *Biochem Pharmacol*. 2011;82(8):828–841.

66. Fabian-Fine R, Skelel P, Errington ML, et al. Ultrastructural distribution of the α7 nicotinic acetylcholine receptor subunit in rat hippocampus. *J Neurosci*. 2001;21(20):7993–8003.

67. Garcia-Rates S, Camarasa J, Sanchez-Garcia AI, Gandia L, Escudero E, Pubill D. The effects of 3,4-methylenedioxymethamphetamine (MDMA) on nicotinic receptors: intracellular calcium increase, calpain/caspase 3 activation, and functional upregulation. *Toxicol Appl Pharmacol*. 2010;244(3):344–353.

68. Schedel A, Thornton S, Schloss P, Klüter H, Bugert P. Human platelets express functional α7-nicotinic acetylcholine receptors. *Arterioscler Thromb Vasc Biol*. 2011;31(4):928–934.

69. Hershey AD. CGRP – The next frontier for migraine. *N Engl J Med*. 2017;377(22):2190–2191.

70. Giambardino MA, Costantini R. Challenging chronic migraine: targeting the CGRP receptor. *Lancet Neurol*. 2017;16(6):410–411.

71. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. *N Engl J Med*. 2017;377(22):1111–1122.

72. Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. *Lancet Neurol*. 2015;14(11):1091–1100.

73. Paul LD. Calcitonin gene-related peptide (CGRP) and migraine. *Headache*. 2006;46(Suppl 1):S3–S8.

74. Rubboli F, Court JA, Sala C, et al. Distribution of nicotinic receptors in the human hippocampus and thalamus. *Eur J Neurosci*. 1994;6(10):1596–1604.

75. Baddick CG, Marks MJ. An autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutants. *Biochem Pharmacol*. 2011;82(8):828–841.

76. Fabian-Fine R, Skelel P, Errington ML, et al. Ultrastructural distribution of the α7 nicotinic acetylcholine receptor subunit in rat hippocampus. *J Neurosci*. 2001;21(20):7993–8003.

77. Garcia-Rates S, Camarasa J, Sanchez-Garcia AI, Gandia L, Escudero E, Pubill D. The effects of 3,4-methylenedioxymethamphetamine (MDMA) on nicotinic receptors: intracellular calcium increase, calpain/caspase 3 activation, and functional upregulation. *Toxicol Appl Pharmacol*. 2010;244(3):344–353.

78. Schedel A, Thornton S, Schloss P, Klüter H, Bugert P. Human platelets express functional α7-nicotinic acetylcholine receptors. *Arterioscler Thromb Vasc Biol*. 2011;31(4):928–934.

79. Hershey AD. CGRP – The next frontier for migraine. *N Engl J Med*. 2017;377(22):2190–2191.

80. Giambardino MA, Costantini R. Challenging chronic migraine: targeting the CGRP receptor. *Lancet Neurol*. 2017;16(6):410–411.

81. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. *N Engl J Med*. 2017;377(22):1111–1122.

82. Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. *Lancet Neurol*. 2015;14(11):1091–1100.

83. Paul LD. Calcitonin gene-related peptide (CGRP) and migraine. *Headache*. 2006;46(Suppl 1):S3–S8.

84. Rubboli F, Court JA, Sala C, et al. Distribution of nicotinic receptors in the human hippocampus and thalamus. *Eur J Neurosci*. 1994;6(10):1596–1604.

85. Baddick CG, Marks MJ. An autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutants. *Biochem Pharmacol*. 2011;82(8):828–841.

86. Fabian-Fine R, Skelel P, Errington ML, et al. Ultrastructural distribution of the α7 nicotinic acetylcholine receptor subunit in rat hippocampus. *J Neurosci*. 2001;21(20):7993–8003.

87. Garcia-Rates S, Camarasa J, Sanchez-Garcia AI, Gandia L, Escudero E, Pubill D. The effects of 3,4-methylenedioxymethamphetamine (MDMA) on nicotinic receptors: intracellular calcium increase, calpain/caspase 3 activation, and functional upregulation. *Toxicol Appl Pharmacol*. 2010;244(3):344–353.

88. Schedel A, Thornton S, Schloss P, Klüter H, Bugert P. Human platelets express functional α7-nicotinic acetylcholine receptors. *Arterioscler Thromb Vasc Biol*. 2011;31(4):928–934.

89. Hershey AD. CGRP – The next frontier for migraine. *N Engl J Med*. 2017;377(22):2190–2191.

90. Giambardino MA, Costantini R. Challenging chronic migraine: targeting the CGRP receptor. *Lancet Neurol*. 2017;16(6):410–411.

91. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. *N Engl J Med*. 2017;377(22):1111–1122.

92. Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. *Lancet Neurol*. 2015;14(11):1091–1100.

93. Paul LD. Calcitonin gene-related peptide (CGRP) and migraine. *Headache*. 2006;46(Suppl 1):S3–S8.
